CASI Pharmaceuticals (NASDAQ:CASI) and NanoString Technologies (NASDAQ:NSTG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.
This is a breakdown of recent ratings for CASI Pharmaceuticals and NanoString Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares CASI Pharmaceuticals and NanoString Technologies’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CASI Pharmaceuticals||N/A||N/A||-$27.47 million||($0.32)||-9.81|
|NanoString Technologies||$106.73 million||8.52||-$77.40 million||($2.78)||-9.33|
CASI Pharmaceuticals has higher earnings, but lower revenue than NanoString Technologies. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares CASI Pharmaceuticals and NanoString Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
CASI Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Institutional & Insider Ownership
12.0% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of NanoString Technologies shares are owned by institutional investors. 24.7% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
CASI Pharmaceuticals beats NanoString Technologies on 9 of the 13 factors compared between the two stocks.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
NanoString Technologies Company Profile
NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, CAR-T characterization, protein immune profiling, neuropathology and neuro-inflammation gene expression, Mouse-AD, autoimmune disease gene expression, miRNA expression, and other gene expression panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc, as well as strategic partnership with Bio-Techne Corp. The company was founded in 2003 and is headquartered in Seattle, Washington.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.